Anti-B Cell Antibody Therapies for Inflammatory Rheumatic Diseases

被引：26

作者：

Faurschou, Mikkel ^{[1
]}

Jayne, David R. W. ^{[2
]}

机构：

[1] Rigshosp, Dept Infect Dis & Rheumatol, Copenhagen Univ Hosp, DK-2100 Copenhagen, Denmark

[2] Addenbrookes Hosp, Dept Med, Lupus & Vasculitis Clin, Cambridge CB2 0QQ, England

来源：

ANNUAL REVIEW OF MEDICINE, VOL 65 | 2014年 / 65卷

关键词：

B cell-targeted therapy; rheumatoid arthritis; systemic lupus erythematosus; vasculitis; myositis; Sjogren's syndrome; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-CD20; MONOCLONAL-ANTIBODY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RITUXIMAB PLUS METHOTREXATE; DAILY ORAL CYCLOPHOSPHAMIDE; DOUBLE-BLIND; INADEQUATE RESPONSE; PHASE-III; WEGENERS-GRANULOMATOSIS; ARTHRITIS PATIENTS;

D O I：

10.1146/annurev-med-070912-133235

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Several monoclonal antibodies targeting B cells have been tested as therapeutics for inflammatory rheumatic diseases. We review important observations from randomized clinical trials regarding the efficacy and safety of anti-B cell antibody-based therapies for rheumatoid arthritis, systemic lupus erythematosus, antineutrophil cytoplasmic antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sjogren's syndrome. For some anti-B cell agents, clinical benefits have been convincingly demonstrated, while other B cell-targeted therapies failed to improve outcomes when added to standard-of-care treatment or were associated with increased rates of adverse events. Although the risk-benefit balance seems to be acceptable for currently licensed anti-B cell agents, additional studies are required to fully assess the safety of treatment regimens involving prolonged interference with B cell counts and functions in rheumatic disorders. Future studies should also evaluate how to maintain disease control by means of conventional and/or biologic immunosuppressants after remission-induction with anti-B cell antibodies.

引用

页码：263 / 278

页数：16

共 73 条

[1] Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis [J].

Benucci, Maurizio ;

Saviola, Gianantonio ;

Manfredi, Mariangela ;

Sarzi-Puttini, Piercarlo ;

Atzeni, Fabiola .

BIOLOGICS-TARGETS & THERAPY, 2013, 7 :69-75

[2] Mortality in systemic lupus erythematosus [J].

Bernatsky, S. ;

Boivin, J. -F. ;

Joseph, L. ;

Manzi, S. ;

Ginzler, E. ;

Gladman, D. D. ;

Urowitz, M. ;

Fortin, P. R. ;

Petri, M. ;

Barr, S. ;

Gordon, C. ;

Bae, S. -C. ;

Isenberg, D. ;

Zoma, A. ;

Aranow, C. ;

Dooley, M. -A. ;

Nived, O. ;

Sturfelt, G. ;

Steinsson, K. ;

Alarcon, G. ;

Senecal, J. -L. ;

Zummer, M. ;

Hanly, J. ;

Ensworth, S. ;

Pope, J. ;

Edworthy, S. ;

Rahman, A. ;

Sibley, J. ;

El-Gabalawy, H. ;

McCarthy, T. ;

Pierre, Y. St. ;

Clarke, A. ;

Ramsey-Goldman, R. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2550-2557

[3]

Björnådal L, 2004, J RHEUMATOL, V31, P713

[4] Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis [J].

Buch, Maya H. ;

Smolen, Josef S. ;

Betteridge, Neil ;

Breedveld, Ferdinand C. ;

Burmester, Gerd ;

Doerner, Thomas ;

Ferraccioli, Gianfranco ;

Gottenberg, Jacques-Eric ;

Isaacs, John ;

Kvien, Tore K. ;

Mariette, Xavier ;

Martin-Mola, Emilio ;

Pavelka, Karel ;

Tak, Paul P. ;

van der Heijde, Desiree ;

van Vollenhoven, Ronald F. ;

Emery, Paul .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :909-920

[5] Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].

Cervera, R ;

Khamashta, MA ;

Font, J ;

Sebastiani, GD ;

Gil, A ;

Lavilla, P ;

Mejía, JC ;

Aydintug, AC ;

Chwalinska-Sadowska, H ;

de Ramón, E ;

Fernández-Nebro, A ;

Galeazzi, M ;

Valen, M ;

Mathieu, A ;

Houssiau, FD ;

Caro, N ;

Alba, P ;

Ramos-Casals, M ;

Ingelmo, M ;

Hughes, GRV .

MEDICINE, 2003, 82 (05) :299-308

[6] Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis [J].

Clifford, David B. ;

Ances, Beau ;

Costello, Craig ;

Rosen-Schmidt, Shari ;

Andersson, Magnus ;

Parks, Deborah ;

Perry, Arie ;

Yerra, Raju ;

Schmidt, Robert ;

Alvarez, Enrique ;

Tyler, Kenneth L. .

ARCHIVES OF NEUROLOGY, 2011, 68 (09) :1156-1164

[7] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[8] Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate [J].

Cohen, Stanley B. ;

Keystone, Edward ;

Genovese, Mark C. ;

Emery, Paul ;

Peterfy, Charles ;

Tak, Paul Peter ;

Cravets, Matt ;

Shaw, Tim ;

Hagerty, David .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :1158-1161

[9] Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study [J].

Dass, S. ;

Bowman, S. J. ;

Vital, E. M. ;

Ikeda, K. ;

Pease, C. T. ;

Hamburger, J. ;

Richards, A. ;

Rauz, S. ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1541-1544

[10] Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis [J].

de Groot, K ;

Rasmussen, N ;

Bacon, PA ;

Tervaert, JWC ;

Feighery, C ;

Gregorini, G ;

Gross, WL ;

Luqmani, R ;

Jayne, DRW .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2461-2469

← 1 2 3 4 5 6 7 8 →